III. Mechanism

  1. Nonselective Beta Blocker (Beta-1 and Beta-2 Adrenergic Blockade)

IV. Dosing

  1. Dose: 40 mg orally daily
  2. Target: 40 to 80 mg/day
  3. Maximum 240 mg/day (Angina, Migraines, Atrial Fibrillation) to 320 mg/day (Hypertension)
  4. Renal Dysfunction
    1. Start 20 mg orally daily
    2. Decrease dosing frequency with Renal Insufficiency
      1. Creatinine Clearance 31 to 50 ml/min: Take every 24 to 36 hours
      2. Creatinine Clearance 10 to 30 ml/min: Take every 24 to 48 hours
      3. Creatinine Clearance <10 ml/min: Take every 40 to 60 hours

V. Adverse Effects

VI. Metabolism

  1. Not lipophilic
  2. Renal excretion
  3. Long Half life

VII. Safety

  1. Pregnancy Category C
  2. Avoid in Lactation

IX. References

  1. (2019) Presc Lett, Resource #350503, Comparison of Oral Beta Blockers
  2. (2020) Med Lett Drugs Ther 62(1598): 73-80
  3. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
  4. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

nadolol (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
NADOLOL 20 MG TABLET Generic $0.19 each
NADOLOL 40 MG TABLET Generic $0.32 each
NADOLOL 80 MG TABLET Generic $0.50 each

Ontology: Nadolol (C0027302)

Definition (NCI) A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention.
Definition (MSH) A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D009248
SnomedCT 387482003, 82896009
LNC LP16211-2, MTHU003377
English Nadolol, 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, nadolol, nadolol (medication), NADOLOL, Nadolol [Chemical/Ingredient], Nadolol (product), Nadolol (substance)
Swedish Nadolol
Czech nadolol
Finnish Nadololi
Russian NADOLOL, НАДОЛОЛ
Japanese ナドロール
Polish Nadolol
Spanish nadolol (producto), nadolol (sustancia), nadolol, Nadolol
French Nadolol
German Nadolol
Italian Nadololo
Portuguese Nadolol

Ontology: Corgard (C0591292)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D009248
English corgard, Corgard